Tcs2314|CAS 317353-73-4|DC Chemicals

Cas No.:	317353-73-4
Chemical Name:	TCS 2314
Synonyms:	[1-({(3S)-4-[(4-{[(2-Methylphenyl)carbamoyl]amino}phenyl)acetyl]- 3-morpholinyl}carbonyl)-4-piperidinyl]acetic acid;TCS 2314;1-[[(3S)-4-[2-[4-[[[(2-Methylphenyl)aMino]carbonyl]aMino]phenyl]acety]l-3-Morpholinyl]carbonyl]-4-piperidinediaceticacid;TCS2314;2-[1-[(3S)-4-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]morpholine-3-carbonyl]piperidin-4-yl]acetic acid;CID 11226207;GTPL6590;BDBM17917;Piperidinylacetic acid derivative, 1;Q27088949;1-[[(3S)-4-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acety]l-3-morpholinyl]carbonyl]-4-piperidinediacetic acid;1-[[(3S)-4-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amin;DA-58364;DA-58364;DA-58364;317353-73-4;317353-73-4;317353-73-4;CHEMBL389946;CHEMBL389946;CHEMBL389946;2-(1-{[(3S)-4-[2-(4-{[(2-methylphenyl)carbamoyl]amino}phenyl)acetyl]morpholin-3-yl]carbonyl}piperidin-4-yl)acetic acid;2-(1-{[(3S)-4-[2-(4-{[(2-methylphenyl)carbamoyl]amino}phenyl)acetyl]morpholin-3-yl]carbonyl}piperidin-4-yl)acetic acid;2-(1-{[(3S)-4-[2-(4-{[(2-methylphenyl)carbamoyl]amino}phenyl)acetyl]morpholin-3-yl]carbonyl}piperidin-4-yl)acetic acid;AKOS024457859;AKOS024457859;TCS-2314;AKOS024457859;TCS-2314;CS-0011050;TCS-2314;NCGC00370940-01;CS-0011050;CS-0011050;NCGC00370940-01;NCGC00370940-01;SCHEMBL14558952;SCHEMBL14558952;SCHEMBL14558952;1-[[(3S)-4-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acety]l-3-morpholinyl]carbonyl]-4-piperidinediaceticacid;1-[[(3S)-4-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acety]l-3-morpholinyl]carbonyl]-4-piperidinediaceticacid;1-[[(3S)-4-[2-[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]acety]l-3-morpholinyl]carbonyl]-4-piperidinediaceticacid;HY-12308;HY-12308;HY-12308
SMILES:	O1C([H])([H])C([H])([H])N(C(C([H])([H])C2C([H])=C([H])C(=C([H])C=2[H])N([H])C(N([H])C2=C([H])C([H])=C([H])C([H])=C2C([H])([H])[H])=O)=O)[C@@]([H])(C1([H])[H])C(N1C([H])([H])C([H])([H])C([H])(C([H])([H])C(=O)O[H])C([H])([H])C1([H])[H])=O
Formula:	C₂₈H₃₄N₄O₆
M.Wt:	522.5928
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.